Digital health in difficult-to-treat severe asthma
- PMID: 36963416
- DOI: 10.1016/S2213-2600(23)00012-7
Digital health in difficult-to-treat severe asthma
Conflict of interest statement
WWB reports consultation fees or has previously served on Advisory Boards for Sanofi, Regeneron, GlaxoSmithKline, AstraZeneca, Genentech, and Novartis. SJS has consulted for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Moderna, OM Pharma, Propeller Health, Regeneron, and Sanofi and has received research support from the National Institutes of Health National Heart, Lung and Blood Institute, Propeller Health, and the Colorado Department of Public Health and Environment Cancer, Cardiovascular and Pulmonary Disease Program.
Comment on
-
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial.Lancet Respir Med. 2023 Jul;11(7):591-601. doi: 10.1016/S2213-2600(22)00534-3. Epub 2023 Mar 21. Lancet Respir Med. 2023. PMID: 36963417 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical